#1 Clinical Trials Search in Europe

Jnj-77242113

JNJ-77242113 is an investigational drug currently being studied in clinical trials for its potential in treating moderate-to-severe plaque psoriasis and ulcerative colitis. This article provides an overview of the ongoing research, focusing on the drug’s efficacy, safety, and potential benefits for patients with these chronic inflammatory conditions.

Table of Contents

What is JNJ-77242113?

JNJ-77242113 is an investigational drug being developed for the treatment of moderate-to-severe plaque psoriasis. It is also known by other names such as PN-21235 and PN-235[1]. As an investigational drug, JNJ-77242113 is still being studied in clinical trials and is not yet approved for general use by regulatory authorities.

What conditions does JNJ-77242113 treat?

JNJ-77242113 is primarily being studied for the treatment of moderate-to-severe plaque psoriasis[2]. Plaque psoriasis is a chronic autoimmune condition that causes rapid buildup of skin cells, resulting in scaly, itchy, and inflamed patches on the skin. In some studies, the drug is also being investigated for other forms of psoriasis, including:

  • Generalized pustular psoriasis (GPP): A rare and severe form of psoriasis characterized by widespread redness and pustules on the skin
  • Erythrodermic psoriasis (EP): A severe form of psoriasis that affects most of the body surface[3]

How does JNJ-77242113 work?

JNJ-77242113 is designed to target specific immune responses in the body and skin that contribute to psoriasis[2]. While the exact mechanism is not fully described in the provided information, it is likely that the drug works by modulating the immune system to reduce inflammation and slow down the rapid skin cell growth associated with psoriasis.

How is JNJ-77242113 administered?

JNJ-77242113 is administered orally as a tablet. In various clinical trials, different formulations and dosing regimens are being tested, including:

  • Immediate-release (IR) tablets[4]
  • Delayed-release (DR) tablets[1]
  • Once daily (QD) dosing[5]
  • Twice daily (BID) dosing[5]

The optimal dosing regimen is still being determined through clinical trials.

Clinical trials and effectiveness

Several clinical trials are evaluating the effectiveness of JNJ-77242113 for plaque psoriasis. The main measures of effectiveness include:

  • PASI score: The Psoriasis Area and Severity Index (PASI) is a tool used to measure the severity and extent of psoriasis. Clinical trials are looking at the percentage of patients achieving PASI 75, PASI 90, and PASI 100 responses, which represent 75%, 90%, and 100% improvement in psoriasis symptoms, respectively[6].
  • IGA score: The Investigator’s Global Assessment (IGA) is used to evaluate the overall severity of psoriasis. Trials are assessing the number of patients achieving an IGA score of 0 (cleared) or 1 (minimal)[6].
  • Quality of life measures: Studies are also evaluating improvements in patients’ quality of life using tools like the Dermatology Life Quality Index (DLQI)[6].

Early results from these trials suggest that JNJ-77242113 may be effective in improving psoriasis symptoms and quality of life for many patients, but full results are still pending.

Potential side effects

As with all medications, JNJ-77242113 may cause side effects. In clinical trials, researchers are carefully monitoring for adverse events (AEs) and serious adverse events (SAEs)[2]. Common side effects and their frequency are not yet fully known, as the drug is still in the investigational stage. Patients participating in clinical trials are closely monitored for any unexpected reactions or side effects.

Ongoing research

JNJ-77242113 is currently being studied in various phases of clinical trials, including:

  • Phase 2 trials to determine the optimal dosing and evaluate initial effectiveness[2]
  • Phase 3 trials to further assess efficacy and safety in larger patient populations[6]
  • Studies comparing JNJ-77242113 to placebo and other active treatments like deucravacitinib[7]
  • Long-term extension studies to evaluate the drug’s safety and effectiveness over extended periods[5]

These ongoing studies will help determine if JNJ-77242113 is safe and effective for treating plaque psoriasis and potentially other forms of psoriasis. If the results are positive, the drug may eventually become available as a new treatment option for patients with moderate-to-severe plaque psoriasis.

Aspect Details
Drug Name JNJ-77242113 (also known as PN-21235, PN-235)
Administration Oral tablet (immediate-release and delayed-release formulations)
Main Conditions Studied Moderate-to-severe plaque psoriasis, Ulcerative colitis
Other Conditions Psoriasis in special areas (scalp, genital, palms, soles)
Key Efficacy Measures PASI scores, IGA scores, BSA changes, Quality of life improvements
Safety Assessments Adverse events, laboratory tests, vital signs, physical examinations
Trial Durations Typically 16-52 weeks, with some extending up to 156 weeks
Population Groups Adults, Adolescents, Healthy volunteers (for pharmacokinetic studies)
Notable Features Targets immune responses in body and skin, Potential for long-term use

FAQ

  • What is JNJ-77242113? JNJ-77242113 is an investigational drug being studied for the treatment of moderate-to-severe plaque psoriasis and ulcerative colitis. It targets immune responses in the body and skin that impact these diseases.
  • How is JNJ-77242113 administered? JNJ-77242113 is administered orally as a tablet. Different formulations, including immediate-release and delayed-release tablets, are being tested in various clinical trials.
  • What conditions is JNJ-77242113 being studied for? JNJ-77242113 is primarily being studied for moderate-to-severe plaque psoriasis. It is also being investigated for ulcerative colitis and psoriasis affecting special areas such as the scalp, genitals, palms, and soles.
  • What are the main outcomes being measured in these clinical trials? The main outcomes include improvements in psoriasis severity (measured by PASI scores), changes in body surface area affected, quality of life improvements, and safety assessments such as adverse events and laboratory tests.
  • How long do these clinical trials typically last? The duration of the clinical trials varies, but many last between 16 to 52 weeks, with some including long-term extension periods up to 156 weeks to assess long-term efficacy and safety.

Ongoing Clinical Trials on Jnj-77242113

  • Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Previously Used Biologic Treatments

    Recruiting

    1 1
    Investigated drugs:
    Bulgaria Czechia Denmark Germany Hungary Italy +3

  • Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Germany Hungary Italy Poland Romania Spain

  • Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

    Not yet recruiting

    1 1 1
    Investigated drugs:
    France Germany Hungary Italy Poland Spain

  • Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Denmark Germany Hungary Poland +2

  • Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

    Not recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Czechia Denmark Germany Hungary Poland +1

  • Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    1 1
    Investigated drugs:
    Belgium Czechia France Germany Hungary Italy +3

  • Study on the Effectiveness and Safety of JNJ-77242113 for Treating Plaque Psoriasis in Special Areas for Patients with Moderate to Severe Symptoms

    Not recruiting

    1 1
    Investigated drugs:
    Germany Hungary Poland Spain

  • Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Hungary Italy Poland Spain

Glossary

  • PASI (Psoriasis Area and Severity Index): A system used to measure the severity of psoriasis. It considers the extent of skin involvement and the degree of redness, thickness, and scaling. Scores range from 0 to 72, with higher scores indicating more severe disease.
  • IGA (Investigator's Global Assessment): A tool used by healthcare providers to assess the overall severity of a patient's psoriasis. It typically uses a scale from 0 (cleared) to 4 (severe).
  • BSA (Body Surface Area): A measure used to determine the percentage of the body affected by psoriasis or other skin conditions.
  • DLQI (Dermatology Life Quality Index): A questionnaire that assesses how much a skin problem has affected a person's life over the previous week. It covers various aspects such as symptoms, daily activities, and personal relationships.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical study, whether or not it is related to the treatment being studied.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes persistent or significant disability, or is otherwise considered medically important.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Placebo: An inactive substance that looks like the drug being tested but contains no active ingredient. It is used as a control in clinical trials to help determine the true effects of the investigational drug.
  • Clinical Response: In the context of ulcerative colitis trials, this typically refers to a significant improvement in symptoms and disease activity scores.
  • Clinical Remission: A state where the signs and symptoms of a disease are significantly reduced or absent. In ulcerative colitis, it often means minimal or no symptoms and improved endoscopic findings.

References

  1. https://clinicaltrials.gov/study/NCT05357755
  2. https://clinicaltrials.gov/study/NCT05223868
  3. https://clinicaltrials.gov/study/NCT06295692
  4. https://clinicaltrials.gov/study/NCT05703841
  5. https://clinicaltrials.gov/study/NCT05364554
  6. https://clinicaltrials.gov/study/NCT06095115
  7. https://clinicaltrials.gov/study/NCT06143878